Abstract Purpose of Review This paper aims to address the latest findings in
neuroendocrine tumor (NET) theranostics, focusing on new evidence and future directions of …

There is great demand to enhance the efficacy of PRRT through combination with other
anticancer treatments. While research in this area is currently limited, the field is rapidly …

Neuroendocrine tumors (NETs) are a diverse group of tumors that often present late due to
nonspecific symptoms. These tumors frequently express somatostatin receptors (SSRs) …

Neuroendocrine neoplasms (NEN) are rare and heterogeneous tumors, originating mostly
from the gastro-entero-pancreatic (GEP) tract followed by the lungs. Multidisciplinary …

Nuclear medicine plays an increasingly important role in the management neuroendocrine
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …

Somatostatin receptor positron emission tomography/computed tomography using 68 Ga-
labeled somatostatin analogs is the mainstay for the evaluation of receptor status in …

Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in
endocrine tissues throughout the body. Peptide receptor radionuclide therapy (PRRT) has …

Neuroendocrine tumors (NETs) are rare tumors that develop from cells of the
neuroendocrine system and can originate in multiple organs and tissues such as the …

The incidence of neuroendocrine tumours (NETs) is increasing, but curative therapeutic
options are limited because diagnosis is often delayed until the tumour has metastasized …

Neuroendocrine tumors (NET) represent a heterogeneous group of tumors originating from
cells of neuroendocrine origin, which express somatostatin receptors (SSTR). This property …